LY2605541
National Institutes of Health
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
The impact of the novel basal insulin LY2605541 (LY) on hepatic and nonhepatic glucose uptake (non-HGU) was evaluated. Conscious…
There is a clinical rationale for a basal insulin with a predictable action and low inter‐ and intra‐individual variability…
To assess the pharmacokinetics (PK) and glucodynamics (GD) of LY2605541 in patients with type 2 diabetes mellitus.
LY2605541 is a novel basal insulin analog with a prolonged duration of action. Two Phase I studies assessed LY2605541…
Insulin remains the most effective and consistent means of controlling blood glucose levels in diabetes. Since 1946, neutral…
OBJECTIVE To use continuous glucose monitoring (CGM) to evaluate the impact of the novel, long-acting basal insulin analog…
OBJECTIVE To compare effects of LY2605541 versus insulin glargine on daily mean blood glucose as part of a basal-bolus regimen…
Elderly patients with type 2 diabetes mellitus (T2DM) are a rapidly emerging population that presents unique clinical challenges…
OBJECTIVE To evaluate whether LY2605541 results in lower fasting blood glucose (FBG) versus insulin glargine (GL). RESEARCH…
IN BRIEF Biosimilar insulins are likely to enter the insulin landscape as patents for major branded insulin products start to…